Top of the morning to you. Still another shiny day is unfolding here on the Pharmalot corporate campus, where we are coping with a nasty bug. This calls for a hot cup of tea and honey, followed by our usual cup of stimulation (we are a two-fisted drinker). Meanwhile, there is much to do. We trust you feel the same way - meetings and deadlines beckon, after all. So let us all get started. Dig in to the tidbits below and then climb those mountains. Have a good one...
FDA Declines To Approve Two Merck Drugs (Dow Jones)
Abbott's Trilipix May Not Lower Heart Risks: FDA (Reuters)
Panel Recommends New Agency Probe Safey of Health IT (iWatch News)
Glaxo Faces Mediation To Resolve Remaining Avandia Suits (Bloomberg News)
Pharmacies Accuse Pfizer Of Fixing Lipitor Generic Prices (Courthouse News)
Antibiotics Are Overprescribed For Children: Study (Reuters)
Salix To Pay $300M For Oceana Therapeutics (Reuters)
FDA Gives Priority Review To Roche Skin Cancer Drug (Pharma Times)
Glaxo's HPV Vaccine May Cut Need For Pap Smears: Study (Reuters)
Amgen Faces Securities Class Action Lawsuit Over Product Safety (Reuters)
EDITOR'S NOTE: Please check this post for updates throughout the morning
tea kettle thx to mirahartford on flickr